Browse > Article
http://dx.doi.org/10.5483/BMBRep.2014.47.6.198

Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo  

Ku, Sae-Kwang (Department of Anatomy and Histology, College of Oriental Medicine, Daegu Haany University)
Han, Min-Su (Laboratory for Arthritis and Bone Biology, Fatima Research Institute, Daegu Fatima Hospital)
Lee, Min Young (College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Lee, You-Mie (College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Bae, Jong-Sup (College of Pharmacy, CMRI, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
Publication Information
BMB Reports / v.47, no.6, 2014 , pp. 336-341 More about this Journal
Abstract
Endothelial cell protein C receptor (EPCR) plays important roles in blood coagulation and inflammation. EPCR activity is markedly changed by ectodomain cleavage and release as the soluble EPCR. EPCR can be shed from the cell surface, which is mediated by tumor necrosis factor-${\alpha}$ converting enzyme (TACE). Oroxylin A (OroA), a major component of Scutellaria baicalensis Georgi, is known to exhibit anti-angiogenic, antiinflammation, and anti-invasive activities. However, little is known about the effects of OroA on EPCR shedding. Data showed that OroA induced potent inhibition of phorbol-12-myristate 13-acetate (PMA), tumor necrosis factor (TNF)-${\alpha}$, interleukin (IL)-$1{\beta}$ and on cecal ligation and puncture (CLP)-induced EPCR shedding through suppression of TACE expression and activity. In addition, treatment with OroA resulted in reduced PMA-stimulated phosphorylation of p38, extracellular regulated kinases (ERK) 1/2, and c-Jun N-terminal kinase (JNK). These results demonstrate the potential of OroA as an anti-sEPCR shedding reagent against PMA and CLP-mediated EPCR shedding.
Keywords
CLP; EPCR shedding; Oroxylin A; PMA;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Esmon, C. T. (2004) Structure and functions of the endothelial cell protein C receptor. Crit. Care. Med. 32, S298-301.   DOI   ScienceOn
2 Wang, L., Bastarache, J. A., Wickersham, N., Fang, X., Matthay, M. A. and Ware, L. B. (2007) Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am. J. Respir. Cell Mol. Biol. 36, 497-503.   DOI   ScienceOn
3 Xu, J., Qu, D., Esmon, N. L. and Esmon, C. T. (2000) Metalloproteolytic release of endothelial cell protein C receptor. J. Biol. Chem. 275, 6038-6044.   DOI   ScienceOn
4 Kurosawa, S., Stearns-Kurosawa, D. J., Carson, C. W., D'Angelo, A., Della Valle, P. and Esmon, C. T. (1998) Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 91, 725-727.
5 Ghosh, S., Pendurthi, U. R., Steinoe, A., Esmon, C. T. and Rao, L. V. (2007) Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J. Biol. Chem. 282, 11849-11857.   DOI   ScienceOn
6 Lopez-Sagaseta, J., Montes, R., Puy, C., Diez, N., Fukudome, K. and Hermida, J. (2007) Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. J. Thromb. Haemost. 5, 1817-1824.   DOI   ScienceOn
7 Menschikowski, M., Hagelgans, A., Eisenhofer, G. and Siegert, G. (2009) Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. Exp. Cell Res. 315, 2673-2682.   DOI   ScienceOn
8 Buras, J. A., Holzmann, B. and Sitkovsky, M. (2005) Animal models of sepsis: setting the stage. Nat. Rev. Drug. Discov. 4, 854-865.   DOI   ScienceOn
9 Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., Czura, C. J., Roth, J., Warren, H. S., Fink, M. P., Fenton, M. J., Andersson, U. and Tracey, K. J. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U.S.A. 101, 296-301.   DOI   ScienceOn
10 Thalhamer, T., McGrath, M. A. and Harnett, M. M. (2008) MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford). 47, 409-414.
11 Leng, Y., Steiler, T. L. and Zierath, J. R. (2004) Effects of insulin, contraction, and phorbol esters on mitogen-activated protein kinase signaling in skeletal muscle from lean and ob/ob mice. Diabetes. 53, 1436-1444.   DOI   ScienceOn
12 Bae, J. S. and Rezaie, A. R. (2011) Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118, 3952-3959.   DOI   ScienceOn
13 Kim, D. C., Lee, W. and Bae, J. S. (2011) Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflamm. Res. 60, 1161-1168.   DOI   ScienceOn
14 Miller, M. A., Meyer, A. S., Beste, M. T., Lasisi, Z., Reddy, S., Jeng, K. W., Chen, C. H., Han, J., Isaacson, K., Griffith, L. G. and Lauffenburger, D. A. (2013) ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling. Proc. Natl. Acad. Sci. U.S.A. 110, E2074-2083.   DOI   ScienceOn
15 Huovila, A. P., Turner, A. J., Pelto-Huikko, M., Karkkainen, I. and Ortiz, R. M. (2005) Shedding light on ADAM metalloproteinases. Trends. Biochem. Sci. 30, 413-422.   DOI   ScienceOn
16 Murphy, G. (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 8, 929-941.
17 Li, C., Lin, G. and Zuo, Z. (2011) Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones. Biopharm. Drug. Dispos. 32, 427-445.   DOI   ScienceOn
18 Li, H. N., Nie, F. F., Liu, W., Dai, Q. S., Lu, N., Qi, Q., Li, Z. Y., You, Q. D. and Guo, Q. L. (2009) Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo. Toxicology 257, 80-85.   DOI   ScienceOn
19 Sun, Y., Lu, N., Ling, Y., Gao, Y., Chen, Y., Wang, L., Hu, R., Qi, Q., Liu, W., Yang, Y., You, Q. and Guo, Q. (2009) Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA- MB-435 human breast cancer cells. Eur. J. Pharmacol. 603, 22-28.   DOI   ScienceOn
20 Lu, Z., Lu, N., Li, C., Li, F., Zhao, K., Lin, B. and Guo, Q. (2012) Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol. Lett. 209, 211-220.   DOI   ScienceOn
21 Tseng, T. L., Chen, M. F., Tsai, M. J., Hsu, Y. H., Chen, C. P. and Lee, T. J. (2012) Oroxylin-A rescues LPS-induced acute lung injury via regulation of NF-kappaB signaling pathway in rodents. PLoS One. 7, e47403.   DOI
22 Qu, D., Wang, Y., Song, Y., Esmon, N. L. and Esmon, C. T. (2006) The Ser219- ->Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype. J. Thromb. Haemost. 4, 229-235.
23 Qu, D., Wang, Y., Esmon, N. L. and Esmon, C. T. (2007) Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. J. Thromb. Haemost. 5, 395-402.   DOI   ScienceOn
24 Fukudome, K., Kurosawa, S., Stearns-Kurosawa, D. J., He, X., Rezaie, A. R. and Esmon, C. T. (1996) The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor. J. Biol. Chem. 271, 17491-17498.   DOI   ScienceOn
25 Mosnier, L. O., Zlokovic, B. V. and Griffin, J. H. (2007) The cytoprotective protein C pathway. Blood 109, 3161- 3172.   DOI   ScienceOn
26 Kurosawa, S., Stearns-Kurosawa, D. J., Hidari, N. and Esmon, C. T. (1997) Identification of functional endothelial protein C receptor in human plasma. J. Clin. Invest. 100, 411-418.   DOI   ScienceOn
27 Han, H., Du, B., Pan, X., Liu, J., Zhao, Q., Lian, X., Qian, M. and Liu, M. (2010) CADPE inhibits PMA-stimulated gastric carcinoma cell invasion and matrix metalloproteinase-9 expression by FAK/MEK/ERK-mediated AP-1 activation. Mol. Cancer Res. 8, 1477-1488.   DOI
28 Fukudome, K. and Esmon, C. T. (1994) Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J. Biol. Chem. 269, 26486- 26491.
29 Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Metz, C., Miller, E. J., Tracey, K. J. and Ulloa, L. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10, 1216-1221.   DOI   ScienceOn
30 Borgel, D., Bornstain, C., Reitsma, P. H., Lerolle, N., Gandrille, S., Dali-Ali, F., Esmon, C. T., Fagon, J. Y., Aiach, M. and Diehl, J. L. (2007) A comparative study of the protein C pathway in septic and nonseptic patients with organ failure. Am. J. Respir. Crit. Care Med. 176, 878-885.   DOI   ScienceOn